Pulmonary Arterial Hypertension

When patients are treated in primary care for high blood pressure, sociodemographic factors sway the rates at which they access patient portals, investigators found. This could influence their hypertension outcomes.

A study found that prehospital blood pressure (BP) reduction had no impact on functional outcomes among patients with undifferentiated acute stroke, but that it may decrease the odds of poor outcomes following hemorrhagic stroke.

Closer monitoring of youth hypertension could lessen the disease in adults, reducing overall costs and morbidity related to cardiovascular disease (CVD), new research shows.

Among over 60,000 nursing home residents who initiated antihypertensive medication, rates of excess fractures due to falls per 100 person-years were as high as 5 among certain patient groups, such as those with dementia and high blood pressure (BP).

A cardiovascular specialist provides an overview of emerging therapies and targets in the PAH treatment space and how they address current unmet needs.

Ronald Oudiz, MD, FACP, FACC, FCCP, discusses the latest guidelines and recommendations for the treatment of pulmonary arterial hypertension (PAH) and how they differ from previous versions.

The randomized trial found that reducing sitting time over a 6-month period was association with reduced systolic blood pressure (BP) among a group of older patients with obesity and high rates of hypertension.

Positive responses seen following experiments involving metastasis-associated in colon cancer 1 (MACC1) indicate that the biomarker can be used to better diagnose and treat patients with pulmonary arterial hypertension (PAH).

Surprisingly, the investigators found people with uncontrolled hypertension before the pandemic actually had a slightly higher chance of getting their blood pressure under control during the crisis.

Adults with pulmonary arterial hypertension (PAH) have a new treatment available with the FDA approval of sotatercept (Winrevair; Merck), an activin signaling inhibitor biologic.

The approval, which marks the first for a once-daily, single-tablet combination therapy for pulmonary arterial hypertension, is based on findings from the phase 3 A DUE study.

Two strategies were tried, but neither outperformed usual care.

Prevalence of hypertension remained 30% throughout the study period and was lower than expected, based on a lower threshold for hypertension endorsed by guidelines in 2017.

Among food-insecure patients on antihypertensive medication, receiving assistance through the Supplemental Nutrition Assistance Program (SNAP) was associated with improvements in medication adherence.

Researchers of the review are underscoring the potential for economic policies to improve the management of hypertension for the millions of people throughout the United States with the condition who are at risk for cardiovascular disease.

Numerous strategies were proposed, including an emphasis on community-based interventions that can reduce psychological stressors associated with clinical settings.

The retrospective study found patients on Bruton’s tyrosine kinase inhibitors are similar to the general population in the sense that it usually takes at least 2 anti-hypertensive drugs to control blood pressure.

For the first time, investigators found that the replacement of salt with a salt substitute not only reduced hypertension, but did not also increase hypotension, a key factor for older adults.

About half of patients receiving the procedure did not need medication to control their blood pressure after 5 years.

The group emphasizes the importance of management strategies that consider 5 types, or groups, of pulmonary hypertension (PH), including 4 types secondary to other conditions.

A multidisciplinary approach is needed in patients with pulmonary arterial hypertension (PAH) who contract COVID-19, as they may experience worse outcomes.

The prognosis and disease severity of pulmonary arterial hypertension (PAH) was found to be associated with changes in trimethylamine N-oxide.

Congenital heart disease and pulmonary arterial hypertension (PAH) associated with congenital heart disease can be immediately detected using chest radiograph-based artificial intelligence (AI), a study found.

Patients with pulmonary arterial hypertension (PAH) had similar efficacy and safety profile when taking either oral Treprostinil or selexipag, indicating that Treprostinil would be an adequate replacement.

A retrospective study found that instances of recurrent pulmonary hypertension due to vascular reocclusion or restenosis were extremely uncommon after balloon pulmonary angioplasty.

This year’s top 5 most-read articles on pulmonary arterial hypertension (PAH) explored expert opinions on treatment approaches, data on newly emerging therapies, the impacts of alcohol, and more.

Increased pulmonary arterial hypertension (PAH) awareness and earlier screening in routine clinical practice could provide an opportunity for earlier treatment, resulting in reduced economic burden for payers, employers, and society at large.

For the first time, researchers identified sex-based differences in genetic expression of human pulmonary microvascular endothelial cells (HPMECs).

At present, it is difficult for clinicians to identify patients at greatest risk for developing preeclampsia with severe features and tailor treatment plans for them; this difficulty increases costs significantly.

In a single-center, retrospective analysis, echocardiography demonstrated low sensitivity but high specificity for diagnosing pulmonary hypertension (PH) in advanced chronic obstructive pulmonary disease (COPD).